These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Bartzokis G; Cummings JL; Markham CH; Marmarelis PZ; Treciokas LJ; Tishler TA; Marder SR; Mintz J Magn Reson Imaging; 1999 Feb; 17(2):213-22. PubMed ID: 10215476 [TBL] [Abstract][Full Text] [Related]
9. Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson's disease. Kim M; Yoo S; Kim D; Cho JW; Kim JS; Ahn JH; Mun JK; Choi I; Lee SK; Youn J Neurol Sci; 2021 Dec; 42(12):5297-5304. PubMed ID: 33860863 [TBL] [Abstract][Full Text] [Related]
10. MRI-derived brain iron, grey matter volume, and risk of dementia and Parkinson's disease: Observational and genetic analysis in the UK Biobank cohort. Casanova F; Tian Q; Williamson DS; Qian Y; Zweibaum D; Ding J; Atkins JL; Melzer D; Ferrucci L; Pilling LC Neurobiol Dis; 2024 Jul; 197():106539. PubMed ID: 38789058 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of QSM over R2* in assessment of parkinson's disease - A systematic review. Saikiran P; Neurol India; 2020; 68(2):278-281. PubMed ID: 32415005 [TBL] [Abstract][Full Text] [Related]
12. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease. Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017 [TBL] [Abstract][Full Text] [Related]
13. MRI assessment of basal ganglia iron deposition in Parkinson's disease. Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346 [TBL] [Abstract][Full Text] [Related]
14. Investigation on positive correlation of increased brain iron deposition with cognitive impairment in Alzheimer disease by using quantitative MR R2' mapping. Qin Y; Zhu W; Zhan C; Zhao L; Wang J; Tian Q; Wang W J Huazhong Univ Sci Technolog Med Sci; 2011 Aug; 31(4):578. PubMed ID: 21823025 [TBL] [Abstract][Full Text] [Related]
15. Value of transverse relaxometry difference methods for iron in human brain. Uddin MN; Lebel RM; Wilman AH Magn Reson Imaging; 2016 Jan; 34(1):51-9. PubMed ID: 26435459 [TBL] [Abstract][Full Text] [Related]
16. Brain iron assessment in patients with First-episode schizophrenia using quantitative susceptibility mapping. Xu M; Guo Y; Cheng J; Xue K; Yang M; Song X; Feng Y; Cheng J Neuroimage Clin; 2021; 31():102736. PubMed ID: 34186296 [TBL] [Abstract][Full Text] [Related]
17. Correlation of R2 with total iron concentration in the brains of rhesus monkeys. Hardy PA; Gash D; Yokel R; Andersen A; Ai Y; Zhang Z J Magn Reson Imaging; 2005 Feb; 21(2):118-27. PubMed ID: 15666406 [TBL] [Abstract][Full Text] [Related]
18. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. Ulla M; Bonny JM; Ouchchane L; Rieu I; Claise B; Durif F PLoS One; 2013; 8(3):e57904. PubMed ID: 23469252 [TBL] [Abstract][Full Text] [Related]
19. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI. Wieler M; Gee M; Martin WR Parkinsonism Relat Disord; 2015 Mar; 21(3):179-83. PubMed ID: 25534153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]